Skip to main content

Table 2 The most important new antibiotic agents in the pipeline

From: Advances in antibiotic therapy in the critically ill

Drug class Drug name Development phase Potential indications
Cephalosporin GSK-2696266 Phase 1 Bacterial infections
 Novel cephalosporin + β-lactamase inhibitor Ceftolozane + tazobactam Approved March 2015 Complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection), hospital-acquired bacterial pneumonia/ventilator associated pneumonia
Ceftaroline + avibactam Phase 2 Complicated urinary tract infections
Ceftazidime + avibactam (CAZ-AVI) Approved 2015 Complicated urinary tract infections, complicated intra-abdominal infections, acute pyelonephritis (kidney infection), hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia
Monobactam + novel β-lactamase inhibitor Aztreonam + avibactam (ATM-AVI) Phase 1 Bacterial infections
Carbapenem + novel β-lactamase inhibitor Carbavance Phase 1 Complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia, febrile neutropenia
MK-7655 + imipenem/cilastatin Phase 2 Complicated urinary tract infections, acute pyelonephritis, complicated intra-abdominal infections
Aminoglycoside Plazomicin Phase 3 Bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant Enterobacteriaceae
Fluoroquinolone WKC 771 Phase 1 Bacterial infections
WKC 2349 (WCK 771 pro-drug) Phase 1 Bacterial infections
Avarofloxacin Phase 2 Community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections
Finafloxacin Phase 2 Complicated urinary tract infections, acute pyelonephritis (kidney infection), acute intra-abdominal infections, acute bacterial skin and skin structure infections
Nemonoxacin Phase 2 Community-acquired bacterial pneumonia, diabetic foot infection, acute bacterial skin and skin structure infections
Zabofloxacin Phase 2 Community-acquired bacterial pneumonia
Delafloxacin Phase 3 Acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, uncomplicated gonorrhea
Oxazolidinone Tedizolid Approved June 2014 Acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia/ventilator acquired bacterial pneumonia
Cadazolid (quinolonyl-oxalidinone) Phase 3 Clostridium difficile-associated diarrhea
Radezolid Phase 2 Acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia
MRX-I Phase 1 Bacterial infections including community-acquired MRSA and vancomycin-resistant enterococci infections
LCB01-0371 Phase 1 Bacterial infections
Lipopeptide and glycopeptide Oritavancin Approved August 2014 Acute bacterial skin and skin structure infections
 Glycopeptide-cephalosporin heterodimer TD-1607 Phase 1 Serious Gram-positive bacterial infections (acute bacterial skin and skin structure infections, hospital-acquired pneumonia/ventilator-associated pneumonia, bacteremia)
  TD-1792 Phase 2 Acute bacterial skin and skin structure infections, other serious infections caused by Gram-positive bacteria, including hospital-acquired pneumonia/ventilator-associated pneumonia and bacteremia
 Lipo-glycopeptide Dalbavancin Approved May 2014 Acute bacterial skin and skin structure infections
  Ramoplanin Phase 2 Clostridium difficile-associated diarrhea
 Lipopeptide Surotomycin Phase 3 Clostridium difficile-associated diarrhea
Macrolide    
 Ketolide Solithromycin Phase 3 Community-acquired bacterial pneumonia, uncomplicated urogenital gonorrhea
 LptD inhibitor POL7080 Phase 2 Ventilator-associated bacterial pneumonia, low respiratory infections
Tetracycline Omadacycline Phase 2 Community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, complicated urinary tract infections
Eravacycline Phase 3 Complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia
Monosulfactam BAL30072 Phase 1 Multidrug-resistant Gram-negative bacterial infections
Fabl inhibitor Debio 1452 Phase 2 Acute bacterial skin and skin structure infections
Debio 1450 (Debio 1452 pro-drug) Phase 1 Bacterial infections
CG-400549 Phase 2 Acute bacterial skin and skin structure infections; osteomyelitis
LpxC inhibitor ACHN-975 Phase 1 Bacterial infections
DNA gyrase inhibitor AZD0914 Phase 1 Uncomplicated gonorrhea
Methionyl-tRNA synthetase (MetRS) inhibitor CRS-3123 Phase 1 C. difficile infection
Peptide deformylase inhibitor GSK-1322322 Phase 2 Acute bacterial skin and skin structure infections
Type 2 topoisomerase inhibitor GSK-2140944 Phase 2 Respiratory tract infections, acute bacterial skin and skin structure infections
Bicyclolide EDP-788 Phase 1 Bacterial infections
Pleuromutilin Lefamulin (BC-3781) Phase 2 Acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia
Elongation factor inhibitor LFF571 Phase 2 C. difficile-associated diarrhea
Fusidane Taksta (fusidic acid) Phase 2 Prosthetic joint infections
Defensin-mimetic Brilacidin Phase 2 Acute bacterial skin and skin structure infections
  SMT19969 Phase 2 C. difficile-associated diarrhea
  1. Adapted from [98] with permission